216 related articles for article (PubMed ID: 28072954)
1. [Clinical and immunological analysis of patients with activated phosphoinositide 3-kinase δ syndrome resulting from PIK3CD mutation].
Tang WJ; Wang W; Luo Y; Wang YP; Li L; An YF; Gou LJ; Ma MS; He TY; Yang J; Zhao XD; Song HM
Zhonghua Er Ke Za Zhi; 2017 Jan; 55(1):19-24. PubMed ID: 28072954
[No Abstract] [Full Text] [Related]
2. [Clinical and genetic analysis for activated PI3K-δ syndrome by PIK3CD gene mutation].
Liu H; Tang XL; Liu JR; Li HM; Zhao SY
Zhonghua Er Ke Za Zhi; 2016 Sep; 54(9):698-702. PubMed ID: 27596086
[TBL] [Abstract][Full Text] [Related]
3. Activated phosphoinositide 3-kinase δ syndrome caused by PIK3CD mutations: expanding the phenotype.
Zhao P; Huang J; Fu H; Xu J; Li T; Zhang X; Meng Q; Zhang L; Tan L; Zhang W; Chen H; Lu X; Ding Y; He X
Pediatr Rheumatol Online J; 2024 Jan; 22(1):24. PubMed ID: 38287413
[TBL] [Abstract][Full Text] [Related]
4. Herpesviruses in the Activated Phosphatidylinositol-3-Kinase-δ Syndrome.
Cohen JI
Front Immunol; 2018; 9():237. PubMed ID: 29599765
[TBL] [Abstract][Full Text] [Related]
5. Report of a Chinese Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome.
Wang Y; Wang W; Liu L; Hou J; Ying W; Hui X; Zhou Q; Liu D; Yao H; Sun J; Wang X
J Clin Immunol; 2018 Nov; 38(8):854-863. PubMed ID: 30499059
[TBL] [Abstract][Full Text] [Related]
6. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
Coulter TI; Chandra A; Bacon CM; Babar J; Curtis J; Screaton N; Goodlad JR; Farmer G; Steele CL; Leahy TR; Doffinger R; Baxendale H; Bernatoniene J; Edgar JD; Longhurst HJ; Ehl S; Speckmann C; Grimbacher B; Sediva A; Milota T; Faust SN; Williams AP; Hayman G; Kucuk ZY; Hague R; French P; Brooker R; Forsyth P; Herriot R; Cancrini C; Palma P; Ariganello P; Conlon N; Feighery C; Gavin PJ; Jones A; Imai K; Ibrahim MA; Markelj G; Abinun M; Rieux-Laucat F; Latour S; Pellier I; Fischer A; Touzot F; Casanova JL; Durandy A; Burns SO; Savic S; Kumararatne DS; Moshous D; Kracker S; Vanhaesebroeck B; Okkenhaug K; Picard C; Nejentsev S; Condliffe AM; Cant AJ
J Allergy Clin Immunol; 2017 Feb; 139(2):597-606.e4. PubMed ID: 27555459
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel de novo gain-of-function mutation of PIK3CD in a patient with activated phosphoinositide 3-kinase δ syndrome.
Luo Y; Xia Y; Wang W; Li Z; Jin Y; Gong Y; He T; Li Q; Li C; Yang J
Clin Immunol; 2018 Dec; 197():60-67. PubMed ID: 30138677
[TBL] [Abstract][Full Text] [Related]
8. Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8
Cannons JL; Preite S; Kapnick SM; Uzel G; Schwartzberg PL
Front Immunol; 2018; 9():1758. PubMed ID: 30116245
[TBL] [Abstract][Full Text] [Related]
9. Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review.
Jamee M; Moniri S; Zaki-Dizaji M; Olbrich P; Yazdani R; Jadidi-Niaragh F; Aghamahdi F; Abolhassani H; Condliffe AM; Aghamohammadi A; Azizi G
Clin Rev Allergy Immunol; 2020 Dec; 59(3):323-333. PubMed ID: 31111319
[TBL] [Abstract][Full Text] [Related]
10. Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity.
Edwards ESJ; Bier J; Cole TS; Wong M; Hsu P; Berglund LJ; Boztug K; Lau A; Gostick E; Price DA; O'Sullivan M; Meyts I; Choo S; Gray P; Holland SM; Deenick EK; Uzel G; Tangye SG
J Allergy Clin Immunol; 2019 Jan; 143(1):276-291.e6. PubMed ID: 29800648
[TBL] [Abstract][Full Text] [Related]
11. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.
Elkaim E; Neven B; Bruneau J; Mitsui-Sekinaka K; Stanislas A; Heurtier L; Lucas CL; Matthews H; Deau MC; Sharapova S; Curtis J; Reichenbach J; Glastre C; Parry DA; Arumugakani G; McDermott E; Kilic SS; Yamashita M; Moshous D; Lamrini H; Otremba B; Gennery A; Coulter T; Quinti I; Stephan JL; Lougaris V; Brodszki N; Barlogis V; Asano T; Galicier L; Boutboul D; Nonoyama S; Cant A; Imai K; Picard C; Nejentsev S; Molina TJ; Lenardo M; Savic S; Cavazzana M; Fischer A; Durandy A; Kracker S
J Allergy Clin Immunol; 2016 Jul; 138(1):210-218.e9. PubMed ID: 27221134
[TBL] [Abstract][Full Text] [Related]
12. Early diagnosis of PI3Kδ syndrome in a 2 years old girl with recurrent otitis and enlarged spleen.
Saettini F; Pelagatti MA; Sala D; Moratto D; Giliani S; Badolato R; Biondi A
Immunol Lett; 2017 Oct; 190():279-281. PubMed ID: 28842185
[TBL] [Abstract][Full Text] [Related]
13. Successful haploidentical hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase δ syndrome: Case report and literature review.
Yang X; Xi R; Bai J; Pan Y
Medicine (Baltimore); 2023 Feb; 102(5):e32816. PubMed ID: 36749229
[TBL] [Abstract][Full Text] [Related]
14. E1021K Homozygous Mutation in PIK3CD Leads to Activated PI3K-Delta Syndrome 1.
Wang Y; Chen X; Yang Q; Tang W; Jia Y; Zhou L; An Y; Zhang Z; Tang X; Zhao X
J Clin Immunol; 2020 Feb; 40(2):378-387. PubMed ID: 31953711
[TBL] [Abstract][Full Text] [Related]
15. Exhaustion of the CD8
Wentink MWJ; Mueller YM; Dalm VASH; Driessen GJ; van Hagen PM; van Montfrans JM; van der Burg M; Katsikis PD
Front Immunol; 2018; 9():446. PubMed ID: 29563914
[TBL] [Abstract][Full Text] [Related]
16. [Clinical features and genotype analysis of 132 patients with Wiskott-Aldrich syndrome].
Li W; Liu D; Zhang X; Ding Y; Zhao X
Zhonghua Er Ke Za Zhi; 2015 Dec; 53(12):925-30. PubMed ID: 26887548
[TBL] [Abstract][Full Text] [Related]
17. Case Report: First Occurrence of Plasmablastic Lymphoma in Activated Phosphoinositide 3-Kinase δ Syndrome.
Yin Z; Tian X; Zou R; He X; Chen K; Zhu C
Front Immunol; 2021; 12():813261. PubMed ID: 34992612
[TBL] [Abstract][Full Text] [Related]
18. [Clinical and immunological characteristics of a case with activated phosphoinositide 3-kinase δ syndrome 2].
Yang QY; Jia YJ; Wang YP; Zeng T; Zhao XD; Zhou LN
Zhonghua Er Ke Za Zhi; 2020 May; 58(5):413-417. PubMed ID: 32392959
[No Abstract] [Full Text] [Related]
19. The First Iranian Cohort of Pediatric Patients with Activated Phosphoinositide 3-Kinase-δ (PI3Kδ) Syndrome (APDS).
Fekrvand S; Delavari S; Chavoshzadeh Z; Sherkat R; Mahdaviani SA; Sadeghi Shabestari M; Azizi G; Arzanian MT; Shahin Shamsian B; Eskandarzadeh S; Eslami N; Rae W; Condino-Neto A; Mohammadi J; Abolhassani H; Yazdani R; Aghamohammadi A
Immunol Invest; 2022 Apr; 51(3):644-659. PubMed ID: 33401995
[TBL] [Abstract][Full Text] [Related]
20. Clinical practice guideline for activated phosphatidyl inositol 3-kinase-delta syndrome in Japan.
Moriya K; Mitsui-Sekinaka K; Sekinaka Y; Endo A; Kanegane H; Morio T; Imai K; Nonoyama S
Immunol Med; 2023 Dec; 46(4):153-157. PubMed ID: 37178059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]